Table 5.
KEGG biological pathways for differentially expressed genes in different stages
| KEGG Pathway Name | Pathway ID | Genes involved | P-Value |
| For intermediate lesions | |||
| Type I Diabetes Mellitus(TIDM) | Hsa04940 | 9 | 0.002 |
| Antigen Processing and Presentation(APP) | Hsa04612 | 13 | 0.003 |
| Complement and Coagulation Cascades(CCC) | Hsa04610 | 12 | 0.003 |
| Cell Adhesion Molecules(CAM) | Hsa04514 | 17 | 0.005 |
| Toll-Like Receptor Signaling Pathway(TLR) | Hsa04620 | 13 | 0.013 |
| Natural Killer Cell Mediated Cytotoxicity(NK) | Hsa04650 | 15 | 0.029 |
| For advanced lesions | |||
| Focal Adhesion(FA) | Hsa04510 | 25 | 0.000 |
| ECM-Receptor Interaction(ECM) | Hsa04512 | 15 | 0.000 |
| Toll-Like Receptor Signaling Pathway(TLR) | Hsa04620 | 13 | 0.002 |
| Regulation of Actin Cytoskeleton(RAC) | Hsa04810 | 20 | 0.005 |
| Fc Epsilon RI Signaling Pathway(FER) | Hsa04664 | 10 | 0.012 |
| MAPK Signaling Pathway(MAPK) | Hsa04010 | 22 | 0.019 |
| Natural Killer Cell Mediated Cytotoxicity(NK) | Hsa04650 | 13 | 0.021 |
| Long-Term Potentiation(LTP) | Hsa04720 | 8 | 0.030 |
| Cell Communication(CC) | Hsa01430 | 12 | 0.032 |
| B Cell Receptor Signaling Pathway(BCR) | Hsa04662 | 8 | 0.042 |
Genes identified from SAM under FDR<1% were tested for overrepresentation within the pathways for the KEGG under the modified Fisher Exact test assumption; p-Value and genes involved in the pathway are provided for each pathway